Adding chemotherapy after surgical procedure for individuals with advanced gastric cancers can reduce mortality risk For individuals with advanced gastric cancer, treatment with chemotherapy after surgery can reduce the threat of cancer related death by 34 percent over five years compared to surgery alone, experts said at the 15th ESMO World Congress in Gastrointestinal Cancer. At the meeting Prof Sung Hoon Noh, a gastric surgeon from Yonsei University College of Medicine, Korea, presented 5-season follow-up from the stage III CLASSIC trial, which added combination chemotherapy to a typical surgical procedure called D2 gastrectomy.We quite definitely anticipate the continued advancement of this program toward the clinic, consistent with our assistance where we expect to start the Stage 1/2 trial in late 2015, with preliminary clinical results expected to end up being reported in early 2016. Individuals who are homozygous for the mutant Z allele make up approximately 95 percent of most people with AAT insufficiency liver disease. These individuals have a lifetime threat of liver disease of 10 percent to 50 percent, that may manifest as cholestatic disease, chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
Previous Post: Allergan agrees to obtain KYTHERA Biopharmaceuticals for $2.
Next Post: And another to go with it.